Simon Tarp

BSc, MSc (Pharmaceutical Sciences), PhD
+45 38 16 41 70
+45 38 16 41 59

In the first semester of 2009 Simon Tarp drew his master’s thesis at Musculoskeletal Statistics Unit, The Parker Institute. In the summer of 2010 Simon was employed as research fellow and from February 2011 until August 2015, he was enrolled as a PhD student at the Faculty of Health Sciences, University of Copenhagen. The PhD project was a collaboration between the Danish Institute for Rational Pharmacotherapy, and The Parker Institute. The aim was to investigate the optimal medical treatment of rheumatoid arthritis, based on side effects, efficacy, and cost based on systematic literature reviews and meta-analysis. From August 2015 dr. Simon Tarp was employed as researcher where he continue his focus on optimal medical treatment now with a more broad perspective including all rheumatic conditions and other disorders, e.g. dermatological and psychiatric. Dr. Tarp works with a broad field of pharmaco-epidemiological methods, where inference from meta-research, study designs, decision making processes, transparency and statistical approaches dominate.

Nationally, dr. Tarp is a methodology consultant for ’The Danish Council for the Use of Expensive Hospital Medicines’ (RADS), where he guide the panel members for the selection of biologic treatment of rheumatological, dermatological, and gastrointestinal conditions, together with thromboprophylaxis therapy in connection with atrial fibrillation. Dr. Tarp is also a RADS guideline panel member for use of antibiotics in both the primary and secondary sector. In 2015 dr. Tarp was employed in the Danish Institute for Rational Pharmacotherapy where he contributes to optimise and rationalise the use of drugs in primary sector in Denmark. From June 2013 until November 2015 Simon was a methodology consultant for The Danish Health Authority in the development of new evidence-based National Clinical Guidelines (Danish: Nationale Kliniske Retningslinjer, NKR).

Internationally, dr. Tarp is a member of the ’Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) Working Group and involved in Task Forces for The European League Against Rheumatism (EULAR).